recently questioned whether the association between cord levels of PCB-153 (poly chlorinated biphenyl-153) and birth weight reported in our recent metaanalysis ) might be attributable to the influence of gestational weight gain (GWG), a factor that may be related to both PCB-153 concentrations and birth weight. By using simulated data in a physiologically based pharmaco kinetic (PBPK) model, 
recently questioned whether the association between cord levels of PCB-153 (poly chlorinated biphenyl-153) and birth weight reported in our recent metaanalysis ) might be attributable to the influence of gestational weight gain (GWG), a factor that may be related to both PCB-153 concentrations and birth weight. By using simulated data in a physiologically based pharmaco kinetic (PBPK) model, 
concluded that
The association between prenatal levels of PCBs and birth weight may be strongly confounded by the effect of [GWG] on both blood PCB levels and birth weight.
In our recently published meta-analysis , the influence of weight gain was considered only in a sensitivity analy sis because we did not have this information from many cohorts at that time. Since the publication of that article, we have obtained more individual-level data on GWG for a number of the cohorts, allowing us to repeat these analyses to further assess such influence.
Seven of the 12 birth cohorts that partici pated in our previous meta-analysis ) had data on GWG available, for a total of 4,473 motherchild pairs. GWG data from 3 cohorts was extracted from pre natal records, whereas for the other cohorts the classification was based on mother's recall. In most cohorts, weight in late pregnancy was obtained at birth or at some weeks before delivery, but in two cohorts these data were obtained some years after birth. In two cohorts, both measured and self-reported data on mother's weight was available, and an excellent correlation was observed (Spearman r = 0.95; p < 0.001). In the present reanalysis of the data, we also estimated the changes in fat mass (FM) as a function of GWG . Spearman correlation coefficients were calculated between PCB-153 and GWG/FM and between GWG/FM and birth weight. We first estimated the association between cord serum PCB-153 and birth weight using linear multivariate-adjusted regression models in each cohort separately, and then we used mixed-effect models to estimate the combined effect (pooled analysis). We included absolute GWG or estimated FM as additional potential confounders in the models.
The absolute GWG and estimated FM distributions were relatively similar among cohorts (mean + SD was 13.9 ± 5.3 kg for GWG and 5.5 ± 4.5 kg for FM). We found low correlations between PCB-153 and GWG/FM and between GWG/FM and birth weight (r < 0.18). The effect estimate of the combined analysis yielded a negative association between PCB-153 and birth weight equivalent to a 293-g reduction [95% confidence interval (CI): -536, -50] in birth weight per 1-µg/L increase in cord serum PCB-153. After including absolute GWG or estimated FM in the model, the strength of the association was reduced by 48% [-153 g (95% CI: -340, 30)] and 31% [-204 g (95% CI: -411, 0)], respectively.
Our reanalysis of earlier data with some new data confirms that GWG may indeed confound the relationship between PCB-153 and birth weight; however, when we included in the model either absolute GWG or estimated FM, which is a more precise estimate of maternal lipid gain , we still observed an important reduction in birth weight as PCB-153 levels increased. We cannot exclude the possibility of residual confounding due to potential measure ment error of GWG, which may further reduce the effect toward the null. However, two of the included cohorts showed high correlations between measured and self-reported weight, suggesting that misclassification due to maternal weight reports is likely to be small and negligible. Misclassification could result from inaccurate assessment of FM. In a recent study, Maple-Brown et al. (2013) observed that maternal age and pre pregnancy body mass index can be related to an increase in gestational FM, suggesting that it is worth considering both of them in models assessing fat mass.
As suggested by , we have considered GWG as a potential confounder because it increases the volume of lipids diluting PCB levels in blood (Glynn et al. 2011 ) and increases birth weight of the offspring (Siega-Riz et al. 2009 ). However, other than a confounding factor, GWG could be an intermediate factor on a causal path between PCB-153 exposure and birth weight. If this is the case, then controlling for GWG in the models would lead to an over adjustment bias (Schisterman et al. 2009 ) in the effect estimates and would be inappropriate if the main aim is to estimate the total (and not the direct) effect of PCB-153 on birth weight.
In conclusion, in interpreting the findings by one should take into account that PBPK models, although useful, are based on many assumptions. The only way to verify them is through testing in population-based studies. Our analysis clearly indicates that attributing all the effect of PCBs on birth weight to GWG appears an oversimplification. In our recent paper , we suggested that gestational weight gain (GWG) confounded the associa tion between pre natal PCB-153 (poly chlorinated Correspondence biphenyl-153) exposure and birth weight observed in the meta-analysis by . Govarts et al. have now performed additional analyses in which they accounted for GWG in cohorts where this information could be abstracted from medical records or questionnaires. Their effort is comm endable and sheds light on results from both our paper and their meta-analysis. In line with our findings, they reported that adjusting for GWG in statistical models of PCB-153 and birth weight substantially reduced the strength of the association, without completely attenuating it.
In Govarts et al.'s reanalysis, adjustment for GWG resulted in a reduction in the association from a 293-g decrease [95% confidence interval (CI): -536, -50] in birth weight per 1-µg/L increase in cord serum PCB-153 to 153 g (95% CI: -340, 30), which represents a 48% reduction in the effect estimate. In comparison, our analyses using pharmacokinetic modeling suggested that 79% of the 150-g (95% CI: -240, -50) reduction in birth weight per 1-µg/L increase in cord serum PCB-153 reported in the original paper by may be attributable to GWG. It is difficult to speculate how much more attenua tion of the PCB-153-birth weight association would occur if it were possible to accurately measure gain in fat mass during pregnancy-the underlying, true confounder-and adjust for it. The data presented by show that only 57.8% of the variability in the amount of fat mass gained in pregnancy is explained by GWG. Sensitivity analyses to assess the influence of such an improved adjustment would be of interest.
In their letter, Govarts et al. touched on the assumptions of pharmaco kinetic models. Both meta-analyses of observational data (Greenland and O'Rourke 2008) and pharmaco kinetic simulations of epidemiologic associations have their strengths, and both can produce results that may appear more precise and conclusive than warranted. In those settings where both approaches can be applied, their results can be combined and used to make an improved inference about an association that neither method can definitively quantify. The example of PCB-153 and birth weight in which confounding by GWG was revealed by pharmaco kinetic modeling and subsequently accounted for in statistical models demonstrates how these two complementary approaches can work hand in hand to generate more robust effect estimates.
Whether some causal (or perhaps any) association exists between environ mental PCB-153 exposure and birth weight is probably beyond the resolution of currently available or practicable methods.
